Compare Moderna, Inc. (MRNA) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs SMX Security Matters plc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while SMX Security Matters plc trades at $3.79 (market cap $4.13M). The key difference: Moderna, Inc. is far larger — about 19043.6× SMX Security Matters plc's market cap, and Moderna, Inc. is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and SMX Security Matters plc for 21 Days on average.
| MRNA | SMX | |
|---|---|---|
Market Cap | $78.65B | $4.13M |
Volume | 37,373,437 | 124,362 |
Sector | Health | Industrials |
52-Week High | $203.46 | $74.08K |
52-Week Low | $22.36 | $3.79 |
Typical Hold Time | 59 Days | 21 Days |
Enterprise Value | $74.80B | -$27.20M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
SMX trades at $3.79, down 2.82% with bearish technical signals despite oversold RSI readings. The company shows severe financial distress with zero revenue, negative $169.18M net income, and negative ROE of -819.22%. Recent news highlights SMX's Digital Material Passport technology gaining media attention from Forbes, TIME, and Boston Herald for recycled plastic verification and 'Made in America' authentication solutions.
The outlook remains highly speculative given the absence of revenue and substantial losses. While technology innovation presents long-term potential, immediate risks include cash burn sustainability and dependence on financing activities. Investors should approach with caution given the fundamental weaknesses and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
